<DOC>
	<DOC>NCT01039558</DOC>
	<brief_summary>We will estimate the responses of lansoprazole and ecabet sodium combination therapy and compare with lansoprazole and placebo therapy in patients who need additional therapy after standard proton pump inhibitor treatment for 4week or more in recurrent gastroesophageal reflux disease.</brief_summary>
	<brief_title>The Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Ecabet</mesh_term>
	<criteria>age 1975 years patients with typical gastroesophageal symptom or erosive reflux esophagitis on gastroduodenoscopy patients with recurrent gastroesophageal symptom after standard proton pump inhibitor treatment for 4 weeks or more patients with gastric ulcer or duodenal ulcer patients with gastric cancer or esophageal cancer pregnant or postpartum women</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>gastroesophageal reflux disease</keyword>
	<keyword>lansoprazole</keyword>
	<keyword>ecabet sodium</keyword>
</DOC>